Cellular Senescence and COVID-19 Long-Hauler Syndrome
Key claim: Senescent cells and their secretome may contribute to COVID-19 Long-Hauler Syndrome, and that rationale is being used to decide whether a clinical trial of senolytic drugs should be initiated.
Abstract
The purpose of this study is to test if senescent cells and their secretome contribute to Long-Hauler Syndrome and if a clinical trial of senolytic drugs, which selectively eliminate senescent cells, should be initiated.
Why this matters
This is the first serious translational bid to move senolytics from geroscience-flavored age-related disease indications into a post-viral syndrome with a large, younger patient population — expanding the ‘senescence-as-driver’ framing beyond chronological aging. If a Long COVID senolytic trial is launched and reads out, it becomes an unusually fast human test of whether clearing senescent cells rescues a defined clinical syndrome, tightening or breaking the mechanism-to-outcome chain that most senolytic pages currently rely on preclinical rescue to support.